PRESS RELEASE

Biotest Supervisory Board extends Management Board contract of Dr Jörg Schüttrumpf by 5 years

• Dr Jörg Schüttrumpf to remain Chief Scientific Officer (CSO) of Biotest AG for another 5 years
• Appointment as Chief Scientific Innovation Officer of Grifols S.A.

Dreieich, 4 September 2023. The Supervisory Board of Biotest AG extended the Management Board contract of Dr Jörg Schüttrumpf (49) by 5 years until 31 August 2028. This is in recognition of his many years of successful work as Head of Research and Development and, since the beginning of 2022, as Chief Scientific Officer (CSO) on the Management Board of Biotest AG.

As 'Chief Scientific Officer', Dr Schüttrumpf is responsible for research and development within the Biotest Group, including drug safety and regulatory affairs. Dr Schüttrumpf has been Head of Global Research at Biotest AG since 2012 and Head of Research and Development since 2015.

In addition, the Spanish parent company of Biotest AG, Grifols S.A., has asked Dr Schüttrumpf to assume the role of 'Chief Scientific Innovation Officer' for the entire Grifols Group. In this role, he will drive the strategic growth focus as a provider of innovative therapeutics for both companies.

"We are very pleased to have Dr Schüttrumpf as a long-term member of the Board of Management and congratulate him on his additional new role in the Grifols Group. He has been very successful in developing the research and development area at Biotest and is a leader with an impressive track record," emphasises Dr Bernhard Ehmer, Chairman of the Supervisory Board of Biotest AG.

About Biotest:

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,300 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).

IR contact

Dr Monika Buttkereit

Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN: DE0005227201
Preference shares: securities’ ID No.  522723; ISIN: DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hannover, München, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.